A recently introduced novel tracer, the 68Ga-N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]-ethylendiamine-N,N diacetic acid-labeled prostate-specific membrane antigen (PSMA) inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (68Ga-PSMA-HBED-CC), has shown promise to improve the local and whole-body staging of patients with PC [12]. This evidence concerns the gene FOLH1 and pachyonychia congenita.